Key Ideas

Autologous stem cell transplant has anchored newly diagnosed multiple myeloma treatment for decades, and every major guideline body still recommends it for eligible patients. But quadruplet induction regimens, MRD-guided maintenance, and increasingly effective cellular therapies at relapse are narrowing the gap. Transplant remains standard for now, though the rationale for reflexively sending every eligible patient straight to transplant deserves fresh scrutiny.

A Question Revisited Every Few Years

Whether to transplant or not to transplant has been asked, and answered, repeatedly over the past three decades as each new class of myeloma drug arrives. Every time novel therapy improves outcomes without transplant, the same question resurfaces: does a patient still benefit enough from high-dose melphalan and stem cell rescue to justify the toxicity, or have modern drug combinations closed the gap? The honest answer today is that transplant still adds measurable benefit for most eligible patients, but the size of that benefit has shrunk as induction and maintenance therapy have improved, and the calculus looks different for an increasing number of patients.

How Transplant Became the Default

Every major guideline group, including the National Comprehensive Cancer Network, American Society of Clinical Oncology, International Myeloma Working Group, and the Mayo Clinic mSMART recommendations, advises referring appropriate patients for autologous stem cell transplant after induction. The rationale traces back to a stark historical baseline: a Mayo Clinic case series of nearly 900 myeloma patients treated in the 1960s with melphalan and prednisone alone showed 66% survival at one year, falling to just 18% at five years. Response rates and survival crept upward through the 1970s and 1980s with combination chemotherapy regimens, but the real inflection point came with high-dose melphalan and stem cell rescue.

The French IFM 90 trial, published in 1996, compared high-dose melphalan with conventional chemotherapy and found response rates rising from 57% to 81%, event-free survival roughly tripling, and five-year overall survival climbing from 12% to 52%, a genuinely practice-changing result at the time. That data, refined over the following two decades at centers doing pioneering transplant work, cemented autologous transplant as the backbone of upfront therapy.

Does Transplant Still Add Benefit With Modern Drug Combinations?

Immunomodulatory drugs, proteasome inhibitors, and now anti-CD38 antibodies have changed the comparison considerably. The IFM 2009 trial randomized newly diagnosed patients to lenalidomide, bortezomib, and dexamethasone (RVD) with or without transplant, and while progression-free survival favored transplant, overall survival was similar between arms, likely reflecting how effective modern salvage therapy has become for patients who relapse after RVD alone. A retrospective analysis using minimal residual disease (MRD) testing on that same trial found that transplant recipients achieved deeper and more frequent MRD negativity than those on RVD alone, evidence that transplant still contributes real disease control even against a strong drug backbone, even as the survival gap between arms narrows.

The PERSEUS trial has since established daratumumab plus VRd (quadruplet induction and consolidation, followed by daratumumab-lenalidomide maintenance) as a new standard for transplant-eligible newly diagnosed myeloma, showing MRD negativity rates at the 10-5 threshold of roughly 75% versus 48% with VRd alone, and more than double the rate of sustained MRD negativity at 12 months. Notably, PERSEUS also allowed maintenance daratumumab to stop once a patient sustained MRD negativity for at least 12 months, a design choice that reflects growing comfort with MRD-guided treatment duration rather than indefinite therapy by default.

MRD Negativity Is Reshaping How the Question Gets Asked

The FDA now accepts MRD negativity as a surrogate endpoint for accelerated drug approval, reflecting how strongly it correlates with long-term outcomes. That shift matters for the transplant question directly: rather than asking only whether transplant improves overall survival, the more useful question has become whether a given patient can reach and sustain deep MRD negativity with or without transplant, and what that depth of response predicts for their individual disease course. High-risk cytogenetics and standard-risk disease both benefit from achieving MRD negativity, but high-risk patients who reach that depth of response still do meaningfully better than those who do not, regardless of how they got there.

Weighing the Real Costs of Upfront Transplant

Melphalan is an excellent drug, and its toxicity profile is well understood, but it is not without long-term consequences. Transplant recipients carry increased risk of second primary malignancies, including solid tumors and secondary myeloid malignancies. Some of this risk likely reflects the alkylating agent itself, some reflects lenalidomide maintenance given afterward, and some may reflect mutational pressure placed on stem cells during collection and reinfusion. These risks have historically been accepted because the alternative, more myeloma and a shorter life, was worse. Whether that trade-off holds as thoroughly now that CAR-T and bispecific antibody options exist at relapse is a fair question.

What Cellular Therapy at Relapse Changes About the Calculation

Ciltacabtagene autoleucel, tested against standard combination therapy in the CARTITUDE-4 trial for patients one to three lines of therapy, produced dramatically better response rates and progression-free survival than standard care. Teclistamab plus daratumumab, evaluated in the MajesTEC-3 trial at first relapse, showed similarly striking results. Curves like these, in the second- or third-line setting, raise a real question about how long transplant will remain the presumed default rather than one option among several effective paths, particularly for older patients already in a deep remission after quadruplet induction.

That said, transplant in first relapse rather than upfront has been shown in older studies to be roughly as effective as transplant given immediately after diagnosis, which means collecting and storing stem cells at diagnosis while deferring the actual transplant remains a reasonable strategy for patients who want to delay the procedure without foreclosing the option later.

Where This Leaves Practice Today

Upfront transplant is not obsolete, and every eligible newly diagnosed patient should still be referred for evaluation after induction. But the case for transplant is no longer built on desperation, as it was in the melphalan-and-prednisone era; it is built on incremental benefit measured against real alternatives, and that benefit is genuinely smaller than it was even ten years ago. As MRD-adapted quadruplet regimens and cellular therapy trials mature, particularly ongoing studies directly comparing cilta-cel to upfront transplant, this question deserves to be asked again, honestly, rather than answered reflexively.

For Patients

Autologous stem cell transplant has been the standard treatment for eligible patients with newly diagnosed multiple myeloma for nearly three decades, and it still adds real benefit for most patients today. The treatment uses a patient's own stem cells, collected in advance, along with high-dose chemotherapy to more deeply suppress the cancer, followed by reinfusion of those stored cells to help the body recover.

Newer combinations of drugs given before transplant, along with newer maintenance approaches guided by highly sensitive tests for residual disease, have narrowed the gap between transplant and non-transplant approaches, though transplant still tends to produce deeper, longer-lasting remissions for most patients able to tolerate it. Newer treatments available at relapse, including CAR-T cell therapy and antibody-based treatments that engage the immune system, are also giving patients and their doctors more options than existed even five years ago.

Patients should discuss with their care team whether transplant makes sense for their specific situation, including their age, other health conditions, and how deep a response they have achieved with initial treatment. Collecting and storing stem cells at diagnosis, even if the actual transplant is delayed, is often a reasonable way to keep this option open without committing to the procedure immediately.

Key Takeaways

  • Every major guideline group still recommends autologous stem cell transplant for eligible newly diagnosed multiple myeloma patients, a recommendation rooted in decades of survival data going back to the pre-transplant era.

  • Modern quadruplet regimens, particularly daratumumab-based combinations studied in PERSEUS, have narrowed but not closed the benefit gap between transplant and non-transplant approaches.

  • MRD negativity, now accepted by the FDA as a surrogate endpoint, is reshaping the transplant question from "does it improve survival" to "does it help a given patient reach and sustain deep remission."

  • Transplant carries real long-term risk, including secondary malignancies, that should be weighed against the benefit it provides in an era of increasingly effective non-transplant and relapse therapies.

  • Cellular therapies such as ciltacabtagene autoleucel and bispecific antibody combinations are producing response rates at relapse that raise legitimate questions about transplant's long-term role, questions that ongoing head-to-head trials should help answer.

References

  1. Attal M, Harousseau JL, Stoppa AM, et al; Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91-97. doi:10.1056/NEJM199607113350204 

  2. Attal M, Lauwers-Cances V, Hulin C, et al; IFM 2009 Study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311-1320. doi:10.1056/NEJMoa1611750

  3. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301-313. doi:10.1056/NEJMoa2312054 

  4. Moreau P, Sonneveld P, Einsele H, et al. Subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone with daratumumab plus lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial. J Clin Oncol. 2025;43(suppl 16):7501. doi:10.1200/JCO.2025.43.16_suppl.7501 

  5. San-Miguel J, Dhakal B, Yong K, et al. Ciltacabtagene autoleucel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379 

  6. Johnson I. Unprecedented results from the phase 3 MajesTEC-3 study support teclistamab plus daratumumab as a potential standard of care as early as second line for relapsed/refractory multiple myeloma. Presented at: American Society of Hematology Annual Meeting; December 2025.